The Gut Onc Lab Podcast podcast

ESMO 2026: (Likely) Practice Changing Presentations We’re Excited About

0:00
33:32
Recuar 15 segundos
Avançar 15 segundos

In this high-velocity conference preview episode of The Gut-Onc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down to dissect the most anticipated late-breaking abstracts heading into ESMO 2026. Scanning the entire gastrointestinal tract, the panel evaluates high-stakes Phase III data drops, novel antibody-drug conjugates (ADCs), PD-1/VEGF bispecifics, and practice-defining de-escalation strategies. 

 

Key Discussion Points
  • Upper GI & Claudin 18.2 ADCs:
    • gHOPE001 (LBA77): Previewing third-line claudin 18.2 ADC efficacy and assessing whether second-generation payloads mitigate historical emetic toxicities.
    • CLARITY-Gastric-01 (LBA7): Analyzing the Phase III data for sonesi-v (sonidesib tugilimumab) in CLDN 18.2-positive gastroesophageal cancers, contrasting statistically significant overall survival (OS) against missed progression-free survival (PFS) endpoints.
    • Long-Term SANO (LBA78) & REMIRAS: Evaluating five-year organ preservation data for clinical complete responders in esophageal cancer, alongside final second-line FOLFIRI-RAM vs. Ram-Pac taxane-pretreated outcomes.
  • Biliary Tract Milestones:
    • HARMONY-GI001: Evaluating first-line avenasimab (PD-1/VEGF bispecific) plus chemotherapy vs. durvalumab plus chemotherapy in advanced biliary tract cancers.
    • ACTICA-1 / ActiCCA-1: Predicting whether six months of adjuvant Gemcitabine + Cisplatin (GemCis) will displace capecitabine (BILCAP) as the definitive post-resection standard of care.
  • Colorectal & MSI-High Landmark Data:
    • CheckMate-8HW Final OS (LBA32): Examining final overall survival curves for frontline Nivo/Ipi vs. single-agent Nivo and chemotherapy in dMMR/MSI-High metastatic colorectal cancer.
    • AZUR-1 (LBA37): Reviewing global Phase II dostarlimab monotherapy results in locally advanced dMMR Stage II/III rectal cancer, detailing why a 100% complete clinical response rate renders randomized surgical control trials obsolete.
    • ECLIPSE Phase II (788ro): Demonstrating why continuing encorafenib + cetuximab beyond progression alongside FOLFIRI prevents MAP-kinase unmasking in BRAF V600E-mutated metastatic colorectal cancer.

Chapters:

00:00 Welcome and Introductions

00:48 Upper GI Preview

00:58 Claudin 18.2 ADC gHOPE001

03:17 CLARITY Gastric 01 Soni V

04:59 SANO Watch and Wait

07:29 REMIRAS Honorable Mention

08:29 Biliary HARMONY GI001 PD1 VEGF

12:51 ACTICA 1 Adjuvant Biliary

17:10 MSI High CRC CheckMate 8HW

20:33 Dostarlimab Rectal Azur 1

25:24 BRAF CRC ECLIPSE Beyond Progression

28:33 More Honorable Mentions and Posters

32:15 Final Thoughts and ESMO Wrap Up

You can find us on X: Gut Onc Lab (@TheGutOncLab) / X 

Mais episódios de "The Gut Onc Lab Podcast"